1. Generics Bulletin
  2. >>Products

Amneal Launches Amicar Rival With CGT Exclusivity

Also Introduces US Rivals To Revatio And Carafate

 
• By Akriti Seth

After receiving FDA approval for its generic aminocaproic acid with 180 days of exclusivity under the agency’s Competitive Generic Therapy pathway, Amneal has launched the rival to Amicar. At the same time, it has also begun selling a generic version of Revatio and has also claimed the first generic rival to Carafate.

Exclusive_Stamp
Amneal will enjoy 180 days of exclusivity for its Amicar rival • Source: Shutterstock

Amneal has launched generic aminocaproic acid 500mg tablets with 180 days of exclusivity in the US, after receiving US Food and Drug Administration approval for the rival to Amicar which had previously been granted a Competitive Generic Therapy designation by the agency.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Products

More from Generics Bulletin

BGMA Becomes Medicines UK

 
• By Dave Wallace

The UK generics and biosimilars industry will now be represented by Medicines UK, the new name for the former British Generic Manufacturers Association.

J&J Denied Injunction Over Private-Label Ustekinumab In US

 
• By Dave Wallace

Stelara originator J&J has been denied in its initial attempt to prevent Samsung Bioepis and ustekinumab biosimilar partner Sandoz from selling a private-label version of the product through a PBM in the US.

UK Forxiga SPCs Wiped Out As Trio Succeed With Plausibility Attack

 
• By Dean Rudge

Generic competition to AstraZeneca’s blockbuster SGLT2 inhibitor Forxiga (dapagliflozin) treatment for diabetes may hit England and Wales earlier than 2028 after a pair of SPCs were invalidated following proceedings initiated by a trio of generics manufacturers.